Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Quester VCT 4 PLC (KAY2)

  Print      Mail a friend       Annual reports

Friday 21 January, 2005

Quester VCT 4 PLC

Final Results

QUESTER VCT 4 PLC ('the Company')

Summary of results for the year ended 31 October 2004

Per Ordinary Share         2004      2003      2002
Capital Values                                     
Net asset value            67.7      77.2      81.8
Share price                62.0      82.5      82.5
Return and Dividends                               
Dividend                      -         -       1.2
Cumulative dividend         2.9       2.9       2.9
Total Return*              70.6      80.1      84.7
Interim dividend for        1.0                    
the year ending 31                                 
October 2005                                       
*Net asset value plus cumulative dividend          

Shareholder information

Annual General Meeting 11.30 a.m. on 22 February 2005

Dividend for 2004/2005 1p

Payment date 1 April 2005

Ex dividend date 2 March 2005

Record date 4 March 2005



During the year, Quester's position in the market continued to attract a strong
flow of investment opportunities. The initial investment phase of the Company
is now essentially complete. The overall funding environment for small
companies is now better than for some time. During the year it was encouraging
that a number of key companies in the portfolio were able to close follow on
funding rounds on satisfactory terms, or are planning to do so shortly. Looking
ahead to possible opportunities for successful sales of new and developing
businesses, it has been encouraging to see a higher level of merger and
acquisition (M&A) activity by larger companies and stock market conditions more
conducive to the achievement of successful flotations, particularly for smaller
companies on the Alternative Investment Market (AIM).

Investments completed

In the current economic environment, with an expectation of relatively low
overall growth and low inflation, it has been the Board's view that a strategy
of investing in high-growth sectors within the economy offers the best
opportunity for the achievement of superior investment returns.

Accordingly, the portfolio of Quester VCT 4, now covering 35 companies
including 29 unquoted companies and six companies whose shares are traded on
AIM or NASDAQ, includes a strong weighting in the ICT and healthcare and life
sciences sectors. The portfolio is well diversified and includes companies
operating in a wide range of markets with high growth potential. Other than in
relation to its early investments and AIM companies, Quester VCT 4 has
generally coinvested alongside Quester's fund for institutional investors, the
Quester Venture Partnership, and other Quester funds. These co-investment
arrangements are appropriate to the needs of ambitious high growth companies,
which may require significant amounts of capital to develop technology based
products or to grow their businesses internationally.

Progress of the portfolio

Shareholders will appreciate that venture capital is a long-term investment
which, in the first few years, may often show a drop in net asset value before
showing any significant uplift, reflecting initial costs and management fees
and the writing down in value of troubled or failed investments which may occur
in the first few years of the life of a fund. At the end of this fourth year,
the portfolio still contains a relatively high proportion of early stage
businesses. In a number of the technology-based sectors in which Quester VCT 4
has holdings, markets have not developed as rapidly as had been anticipated.
Some of the portfolio companies have suffered as a result, with business
performance falling behind plan. Provisions totalling £5.1 million have been
made in respect of 11 unquoted investments. Other portfolio companies have
achieved good progress and show the potential to fulfil expectations.

The Board is confident that, across the portfolio as a whole, progress is
satisfactory at this stage in Quester VCT 4's development and that there are
prospects for substantial upside potential.

Trade sales and flotations

It is encouraging to be able to report that successful trade sales or
flotations of four venture capital investments were achieved during the year.
These included two realisations for cash, which have together produced realised
gains in the year ended 31 October 2004 of £1,443,000.

The other two transactions have resulted in the Company holding quoted stock in
the acquirer and/or an entitlement to future earn-out consideration. At this
stage the sale of CDC Solutions Limited has been accounted for on a no profit/
no loss basis, while the sale of On Demand Distribution Limited to Loudeye
Corporation ('Loudeye') has produced only a modest unrealised gain. Both
transactions offer significant potential for future uplift in valuation,
through share price performance (in the case of Loudeye) and under the earn-out

Net assets, revenue and dividends

During the year, there was a 12.3% reduction in the net asset value per share
of the Company, from 77.2p at 31 October 2003 to 67.7p at 31 October 2004.

The movement in net assets is summarised as follows:

                                                               £'000  Pence per
Net asset value at 31 October 2003                            40,739       77.2
Income                                                           267        0.5
Investment management fee and other expenses                 (1,330)      (2.5)
Realised net gains on disposal of investments                  1,606        3.1
Write-off of investments                                     (1,052)      (2.0)
Net unrealised losses on revaluation of investments          (4,500)      (8.6)
Share buy-backs (serving to enhance NAV by 0.04p per           (490)          -
Net asset value at 31 October 2004                            35,240       67.7

The statement of total return for the year ended 31 October 2004 shows a loss
of £5,009,000, equivalent to 9.5p per share. This comprises a loss of £577,000
on revenue account, with the balance being attributable to capital account.

Against this background, the Directors are not recommending a final dividend
for the year ended 31 October 2004. However, it is intended that the Company
should shortly revoke its investment company status, to enable a dividend to be
paid in respect of the realised gains achieved on venture capital investments
during the year. This will be paid as an interim dividend in respect of the
year ending 31 October 2005 of 1.0p per share, payable on 1 April 2005.

Change of corporate broker and market makers

In July 2004 the Company appointed Noble & Company Limited as its corporate
broker, replacing Evolution Beeson Gregory Limited. Following this change,
Winterflood Securities Limited became market makers in the Company's shares.


The investments completed by the Company are, in most cases, still at an early
stage and will take time to mature.

The Board considers that the portfolio of investments that has now been
constructed, covering a diverse range of companies operating in high-growth
sectors, is capable of delivering attractive returns to shareholders in the
longer term.

Robert Wright


21 January 2005


Progress with venture capital investment

During the year ended 31 October 2004, 11 new investments were completed at an
initial cost of £4.1 million.

The new investments included six in unquoted companies: three in software,
Argelcom Limited (£89,000), Celona Technologies Limited (£321,000) and Digital
Union (UK) Limited (£536,000); one in communications, Amino Technologies plc (£
357,000); one in electronics, Mesophotonics Limited (£893,000); and one in
consumer services, HTC Healthcare Limited (£536,000).

In pursuit of the Company's strategy to invest in attractive companies raising
capital on AIM, a total of £1.3 million was invested in five companies covering
a range of different sectors: Allergy Therapeutics plc, Offshore Hydrocarbon
Mapping plc, Polaron plc, Public Recruitment Group plc and Quadnetics Group

An additional £2.9 million was invested in 16 of the existing portfolio
companies, either as further tranches of originally agreed commitment or as
follow-on investment. The follow-on investments included additional commitments
to Advanced Valve Technologies Limited (£544,000), Cylacel Group plc (£
500,000), Lorantis Holdings Limited (£650,000) and Teraview Limited (£250,000).

As previously reported, the portfolio that we have been building for Quester
VCT 4 is an early stage venture capital portfolio, consisting largely of
technology-related companies serving markets with considerable potential over
the long term.

It is emphasised, however, that most of the companies concerned are still at a
relatively early stage of development. For those involved in technology-related
opportunities, there may at this stage still be only limited, if any, sales
revenues and a reported financial loss. This pattern of financial results
should be appreciated as typical of early-stage companies exploiting
technology-related opportunities and their business plan.

Trade sales and flotations

We are pleased to be able to report that successful trade sales or flotations
of four venture capital investments were achieved during the year, including
two realisations for cash and two transactions resulting in the Company holding
quoted stock in the acquirer and/or an entitlement to future earnout

• The biopharmaceutical company Sterix Limited was sold in February 2004 to the
European pharmaceutical group Ipsen, Quester VCT 4's investment realising cash
proceeds of £1,062,000 and generating a gain of £495,000 on cost of £567,000.

• The holding in Amino Technologies plc, which had been acquired for £357,000
in November 2003 as an unquoted investment, was sold in tranches upon the
admission of the company's shares to trading on AIM in June 2004 and
subsequently, realising total proceeds of £1,305,000 and a gain of £948,000.

• The digital music service provider On Demand Distribution Limited ('OD2') was
acquired by the NASDAQ-quoted company Loudeye Corporation ('Loudeye') in June
2004, to create the largest business-to-business digital media provider in the
world with the largest licensed digital music catalogue in the industry. For
Quester VCT 4, the initial consideration received in the form of Loudeye shares
- based on the last traded price of these shares on NASDAQ, appropriately
discounted - and the accounting value of the deferred consideration receivable
together amount as at 31 October 2004 to £694,000, producing an unrealised gain
at this stage of £126,000. The ultimate return to Quester VCT 4 will depend
upon movements in Loudeye's share price, foreign exchange movements and the
future performance of the business itself (under an earn-out entitlement).

• The software company CDC Solutions Limited ('CDC') was sold in December 2003
to Information Holdings Inc., a US-based information services group (since
acquired by The Thomson Corporation) which is the parent company of Liquent,
Inc. ('Liquent'), hitherto CDC's major competitor. The CDC board and Quester
considered that CDC shareholders would ultimately benefit from a merger of the
two companies and their improved prospects for growth as a combined business.
Quester VCT 4's investment was sold for cash and cash equivalents repaying a
substantial part of the original £1.0 million cost of this investment.
Depending upon the future performance of the combined business over the coming
two years, a good uplift on cost may ultimately be achieved, under an earn-out
entitlement. At 31 October 2004, this transaction has been reflected in the
accounts on a no profit/no loss basis.

In addition, in July 2004 the Company sold its holding in Offshore Hydrocarbon
Mapping plc, which had been acquired for £175,000 in March 2004, realising a
gain of £53,000.

A well balanced portfolio

The portfolio so far established is balanced by sector and well spread. A
summary of the sectors covered by the portfolio at 31 October 2004 is provided
in the table below:

Industry sector                 Existing venture      Valuation       Number of
                                         capital                    investments
                                    portfolio at                               
                                               %          £'000                
Healthcare & life sciences                  33.8          6,368               9
Software                                    23.0          4,330              10
Industrial products & services              12.1          2,270               4
Communications                              11.6          2,184               4
Internet                                     7.2          1,350               2
Electronics                                  6.0          1,125               3
Semiconductors                               3.5            652               2
Consumer goods & services                    2.8            536               1
                                           100.0         18,815              35

Reserves for follow-on investment

The young companies in which Quester VCT 4 has invested will require further
rounds of finance as they grow. It is important that Quester VCT 4 holds
reserves to cover this funding process, provided the companies concerned
continue to make satisfactory progress. This is particularly important for a
portfolio of this type, and is one of the reasons why we consider that a
venture capital portfolio of about 35 investments is appropriate for the

Under the VCT legislation, at least 70% of the Company's investments have to be
represented by qualifying holdings. In order to comply with this requirement
and maintain an appropriate level of reserves, £5.6 million was held in
non-interest bearing cash accounts at the year end (this balance is expected to
be significantly reduced by the end of the current year). This results in a
lower level of interest income but is consistent with managing the venture
capital portfolio appropriately for current market conditions and long-term
capital growth.

Valuation of the venture capital portfolio

The venture capital investments have been valued in line with the Company's
accounting policies, which are based on the valuation guidelines issued by the
British Venture Capital Association ('BVCA') in June 2003.

Holdings in companies whose shares are traded on AIM are valued on the basis of
mid-market price on 31 October 2004. It was disappointing that AIT Group plc,
which had reported satisfactory results for its financial year ended 31 March
2004, was obliged in August 2004 to issue an announcement that expectations for
the year to 31 March 2005 would be lower than anticipated. The share price fell
following that announcement and stood at 33p as at 31 October 2004. For Quester
VCT 4, the effect was a reduction of £1,066,000 over the year in carrying value
of this investment (the valuation at 31 October 2004 being £883,000 against
cost of £1,130,000). Other AIM investments showed a net appreciation in value
of £201,000.

As regards the unquoted investments, in a number of the technology-based
sectors in which Quester VCT 4 has holdings, markets have not developed as
rapidly as had been anticipated. Some of the companies in the Quester VCT 4
portfolio have suffered as a result, with business performance falling behind
plan. Provisions have been made against cost of the investments concerned:
these total £5.1 million in respect of 11 unquoted investments, including
Advanced Valve Technologies Limited (£74,000), Anadigm Limited (£1,055,000),
Anthropics Technology Limited (£250,000), Arithmatica Limited (£1,057,000),
First Index Limited (£1,030,000), Mesophotonics Limited (£223,000), Nexagent
Limited (£311,000), Nomad Software Limited (£450,000), Printable Field Emitters
Limited (£22,000) and Reqio Limited (£580,000). The investments in First Index
Group Limited and Printable Field Emitters Limited have now been treated as

Teraview Limited closed a new funding round at a higher price, resulting in a
valuation uplift of £108,000. The carrying value of the investment in Sift
Group plc has been reduced by £219,000 to reflect current valuation conditions
in the venture capital market.

Overall, write-offs resulting from business failures totalled £1.0 million,
while the net reduction in carrying value of the ongoing portfolio of unquoted
venture capital investments amounted to £4.1 million.

As at 31 October 2004, the Company held entitlements to additional earn-out
consideration following two of the trade sales (CDC and OD2), which may in due
course add to the overall portfolio valuation.

Listed equity and bond portfolios

At 31 October 2004 the Company retained bonds to a value of £876,000. In
addition, at 31 October 2004 the Company held a portfolio of listed equities
valued at £6.1 million (showing an unrealised capital profit of £312,000).


As at the date of this report, the initial investment phase of the Company is
essentially complete with a portfolio of 35 venture capital investments. The
total number of venture capital investments will be kept under review and
further investments will be made if appropriate. While a number of the
companies in which Quester VCT 4 has invested have not met their objectives
during the period, it is pleasing to see a significant evolution of the
portfolio with a number of trade sales and flotations having been achieved
which will lead in due course to full realisation of these investments. Other
portfolio companies continue to show the potential to fulfil expectations.
Overall, we are confident that the portfolio has substantial upside potential.

Quester Capital Management Limited


21 January 2005


Quoted venture        Industry sector     Original Valuation Equity % % of fund 
Investments                               cost               held     by value  
                                          £'000    £'000                        
AIT Group plc         Software            1,130    883       5.8%     2.5%      
Allergy Therapeutics  Healthcare and life 500      510       1.1%     1.4%      
plc                   sciences                                                  
Loudeye Corp.         Internet            568      694       0.8%     2.0%      
Polaron plc           Industrial products 250      308       1.2%     0.9%      
                      and services                                              
Public Recruitment    Industrial products 250      233       0.8%     0.6%      
Group plc             and services                                              
Quadnetics Group plc  Electronics         143      167       0.5%     0.5%      
Total quoted venture capital investments  2,841    2,795              7.9%      
Unquoted venture                                                                
Advanced Valve        Industrial products 1,062    729       26.4%      2.1%    
Technologies Limited  and services                                              
Anadigm Limited       Semiconductors      1,278    223       2.8%       0.6%    
Antenova Limited      Communications      999      750       6.8%       2.1%    
Anthropics Technology Communications      1,070    70        7.0%       0.2%    
Argelcom Limited      Software            89       89        6.2%       0.3%    
Arithmatica Limited   Semiconductors      1,486    429       13.7%      1.2%    
Avidex Limited        Healthcare & life   801      801       2.8%       2.3%    
Azea Networks, Inc    Communications      1,332    1,332     6.8%       3.8%    
BlazePhotonics        Communications      514      32        2.9%       0.1%    
Celona Technologies   Software            321      321       9.0%       0.9%    
Celoxica Holdings     Software            1,148    648       2.8%       1.9%    
Cyclacel Group plc    Healthcare & life   1,000    1,000     1.4%       2.9%    
De Novo               Healthcare & life   750      187       2.8%       0.5%    
Pharmaceuticals       sciences                                                  
Digital Union UK      Software            536      536       13.4%      1.5%    
Elateral Holdings     Software            1,155    155       15.5%      0.5%    
Footfall Limited      Industrial products 1,000    1,000     7.7%       2.8%    
                      and services                                              
HTC Healthcare Group  Consumer goods and  536      536       8.7%       1.5%    
plc                   services                                                  
Lorantis Holdings     Healthcare & life   1,400    1,025     2.5%       2.9%    
Limited               sciences                                                  
Mesophotonics Limited Electronics         893      670       6.0%       1.9%    
Nexagent Limited      Software            467      117       1.2%       0.3%    
Nomad Software        Software            1,087    537       6.5%       1.5%    
Opsys Limited         Electronics         1,038    288       2.9%       0.8%    
Oxford Immunotec      Healthcare & life   625      625       9.6%       1.8%    
Limited               sciences                                                  
Oxxon Therapeutics    Healthcare & life   987      987       3.5%       2.8%    
Holdings, Inc.        sciences                                                  
Reqio Limited         Software            624      44        12.2%      0.1%    
Sift Group Limited    Internet            875      656       4.5%       1.9%    
Teraview Limited      Healthcare & life   625      733       4.9%       2.1%    
Workshare Limited     Software            1,000    1,000     6.6%       2.8%    
Xention Discovery     Healthcare & life   500      500       5.8%       1.4%    
Limited               sciences                                                  
Total unquoted venture capital            25,198   16,020              45.5%    
Total venture capital                     28,039   18,815              53.4%    
Listed fixed interest                     852      876                 2.5%     
Listed equity investments                 5,811    6,123               17.4%    
Total investments                         34,702   25,814              73.3%    
Cash and other net assets                 9,426    9,426               26.7%    
Net assets                                44,128   35,240              100%     

STATEMENT OF TOTAL RETURN (incorporating the revenue account)


                      Notes    2004     2004     2004    2003    2003    2003
                            Revenue  Capital    Total Revenue Capital   Total
                              £'000    £'000    £'000   £'000   £'000   £'000
Loss on investments               -  (3,946)  (3,946)       - (2,056) (2,056)
Income                  2       267        -      267   1,016       -   1,016
Investment management   3     (486)    (486)    (972)   (501)   (501) (1,002)
Other expenses          4     (358)        -    (358)   (436)       -   (436)
Return on ordinary            (577)  (4,432)  (5,009)      79 (2,557) (2,478)
activities before tax                                                        
Tax on ordinary         6         -        -        -       5     (1)       4
Return on ordinary            (577)  (4,432)  (5,009)      84 (2,558) (2,474)
activities after tax                                                         
Dividends proposed                -        -        -       -       -       -
Transfer (from)/ to           (577)  (4,432)  (5,009)      84 (2,558) (2,474)
Return per share        7    (1.1)p   (8.4)p   (9.5)p    0.2p  (4.8)p  (4.6)p

The revenue column of this statement is the profit and loss account of the

All revenue and capital items in the above statement derive from continuing

The Company has only one class of business and derives its income from
investments made in shares and securities and from bank deposits.

The accompanying notes are an integral part of this statement.



                                                Note        2004      2003     
                                                            £'000     £'000    
Fixed assets                                                                   
Investments                                                 25,814    26,687   
Current assets                                                                 
Debtors                                                     578       609      
Cash at bank                                                9,185     13,809   
                                                            9,763     14,418   
Creditors (amounts falling due within one year)             (237)     (266)    
Net current assets                                          9,526     14,152   
Creditors (amounts falling due in over one                  (100)     (100)    
Net assets                                                  35,240    40,739   
Capital and reserves                                                           
Called-up equity share capital                              520       528      
Share premium                                               218       218      
Special reserve                                             41,975    49,466   
Capital reserve - realised                                  619       (3,993)  
- unrealised                                                (7,637)   (5,602)  
Revenue reserve                                             (455)     122      
Equity shareholders' funds                                  35,240    40,739   
Net asset value per share                           15      67.7p     77.2p    

The financial statements were approved by the directors on 21 January 2005 and
were signed on their behalf by:

Robert Wright


The accompanying notes are an integral part of this statement.



                                                  Notes   2004         2003    
                                                          £'000        £'000   
Cash outflow from operating activities                    (1,030)      327     
Corporation tax paid                                      -            (23)    
Financial investment                                                           
Purchase of venture capital investments                   (6,993)      (6,496) 
Purchase of listed equities and fixed interest            (2,557)      (25,083)
Sale/redemption of venture capital investments            3,715        108     
Sale/redemption of listed equity and fixed                2,731        44,248  
interest investments                                                           
Total financial investment                                (3,104)      12,777  
Equity dividends paid                                     -            (607)   
Issue of shares in accordance with the terms of           -            82      
the dividend reinvestment scheme                                               
Buy back of shares                                        (490)        (67)    
Total financing                                           (490)        15      
(Decrease) / increase in cash for the period              (4,624)      12,489  
Reconciliation of net cash flow to movement                                    
in net funds                                                                   
(Decrease) / increase in cash for the period              (4,624)      12,489  
Net funds at the start of the period                      13,809       1,320   
Net funds at the end of the period                        9,185        13,809  

The accompanying notes are an integral part of this statement.


2 Income                                                  2004       2003      
                                                          £'000      £'000     
Dividend income                                                                
Listed equity shares                                      179        132       
Interest receivable                                                            
Fixed interest securities                                 39         735       
Loans to unquoted companies                               -          4         
Bank deposits                                             40         137       
Sundry income                                             9          8         
                                                          267        1,016     

3 Investment management fee

Quester Capital Management Limited ('QCML') provides investment management
services to the Company under an agreement dated 30 October 2000.

A charge of £972,000 (2003: £1,002,000) in respect of the management fee
payable to QCML was accrued during the year together with irrecoverable VAT of
£181,000 (2003: £185,000). The fee, which is calculated monthly and is payable
in advance, was levied at a rate of 2.5% (2003: 2.5%) on the Company's net
assets during the financial year ended 31 October 2004.

The manager's appointment is for a fixed term which shall expire on the seventh
anniversary of the commencement of the fund and shall continue until terminated
by either party subject to a notice period. If such notice is given on or after
the seventh anniversary of the commencement of the fund, the notice period
shall be the longer of (i) twelve months and (ii) the period from the date on
which notice is given to the tenth anniversary of the commencement of the fund.
Thereafter the notice period shall be twelve months.

The management fee payable to Newton Investment Management Limited, to the
extent that it is not covered by transaction fees payable by the Company, will
be met by QCML out of the above fee.

QCML provides administrative and secretarial services to the Company for which
it is entitled to a fee of £53,000 per annum (linked to the movement in the
RPI). This fee is included in other expenses (note 4).

4 Other expenses                                        2004        2003       
                                                        £'000       £'000      
Administrative and secretarial services                 53          51         
Directors' remuneration (note 5)                        39          39         
Auditor's remuneration                                                         
- audit services                                        22          21         
- non audit services                                    9           10         
Insurance                                               11          7          
Legal and professional expenses                         21          27         
UKLA, LSE and registrars fees                           19          21         
Other expenses                                          (7)         43         
Irrecoverable VAT                                       191         217        
                                                        358         436        

5 Directors' remuneration

                                                        2004       2003        
                                                        £'000      £'000       
Fees paid to directors                                  15         15          
Amounts paid to third parties, excluding VAT, in        24         24          
consideration of the services of directors                                     
                                                        39         39          

6 Tax on ordinary activities

                                2004        2004         2003        2003       
                                Revenue     Capital      Revenue     Capital    
                                £'000       £'000        £'000       £'000      
Corporation tax payable -prior  -           -            5           (1)        
year adjustment                                                                 
                                -           -            5           (1)        
Reconciliation of profit on                                                     
ordinary activities to taxation                                                 
                                2004        2004         2003        2003       
                                Revenue     Capital      Revenue     Capital    
                                £'000       £'000        £'000       £'000      
(Loss)/ profit on ordinary      (577)       (4,432)      79          (2,557)    
activities before tax                                                           
Tax on profit on ordinary       (173)       (1,330)      24          (767)      
activities at standard UK                                                       
corporation tax rate at 30%                                                     
Effects of:                                                                     
Loss on investments             -           1,184        -           617        
Loss on operating activities    173         146          (24)        150        
Prior year adjustment           -           -            5           (1)        
                                -           -            5           (1)        

7 Return per share

The revenue loss per share of 1.1p (2003: profit of 0.2p) is based on the
aggregate of the net loss from ordinary activities after tax of £577,000 (2003:
profit of £84,000) and on ordinary shares of 52,471,757 (2003: 52,791,612),
being the weighted average number of shares in issue during the year.

The capital loss per share of 8.4p (2003: 4.8p) is based on the net realised
and unrealised capital loss for the period after tax of £4,432,000 (2003: £
2,558,000) and on ordinary shares of 52,471,757 (2003: 52,791,612), being the
weighted average number of shares in issue during the year.

15 Net asset value per share

The net asset value per share as at 31 October 2004 of 67.7p (2003: 77.2p) is
based on net assets of £35,240,000 (2003: £40,739,000) divided by the
52,047,965 (2003: 52,781,815) ordinary shares in issue at that date.

The financial information set out above does not constitute the Company's
statutory accounts for the year ended 31 October 2004. The statutory accounts
for the year ended 31 October 2004 will be finalised on the basis of the
financial information presented by the directors in the preliminary
announcement and will be delivered to the Registrar of Companies following the
Company's Annual General Meeting.

A copy of the above document has been submitted to the UK Listing Authority,
and will shortly be available for inspection at the UK Listing Authority's
Document Viewing Facility, which is situated at:

Financial Services Authority

25 The North Colonnade

Canary Wharf


E14 5HS

Copies of the full financial statements for the year ended 31 October 2004 are
expected to be posted to shareholders on 25 January 2004 and will be available
to the public at the registered office of the Company at 29 Queen Anne's Gate,
London, SW1H 9BU.


a d v e r t i s e m e n t